• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Saudi Arabia·Healthcare·4002.SR
Share

Mouwasat Medical Services Company Stocks

SAR 55.45Last Updated 26.10.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Moderate

Recommendation

Hold

Market Cap

SAR 2.96B

SAR 55.45
Key Takeaways

Risk factor

Very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Excellent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Mouwasat Medical Services Company, established in 1974 and headquartered in Dammam, Saudi Arabia, is a prominent healthcare provider. The company's core activities involve the acquisition, management, and operation of a wide array of medical facilities, including hospitals, clinics, pharmacies, and drugstores throughout the Kingdom of Saudi Arabia. Mouwasat operates an extensive chain of hospitals located in key cities such as Dammam, Jubail, Madinah, Khobar, Qatif, and Riyadh, delivering comprehensive medical care to its patients. Beyond general hospital services, the company features specialized centers addressing various health needs. These include dedicated skin care facilities offering cosmetic dermatology, laser treatments, reconstructive and plastic surgery, beauty services, and weight loss programs. It also provides a fertility center and a specialized clinic for bariatric surgery. Further expanding its specialized offerings, Mouwasat boasts a cardiology center for the diagnosis and treatment of heart conditions, a dedicated stroke unit, and a facility focused on managing diabetes and diabetic foot complications. The company also extends its services to include long-term care and rehabilitation. Additionally, Mouwasat Medical Services Company is active in the wholesale distribution of medical equipment and pharmaceutical products.

Company Valuation

Fairly valued
4/7

From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E, of fair value on EV

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 4002.SR is 84.2 and suggests 51.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.10.2026 03:18

"The conditions for a rebound are ripe": Stocks rise for a second day ahead of big tech earnings reports

28.10.2026 03:13

Oracle is expanding its partnership with OpenAI and integrating Google chips into its infrastructure

28.10.2026 00:20

Memory stocks cool off in 2H26 amid AI spending doubts

27.10.2026 22:38

GM will move its listing to the Nasdaq. What does this mean for its stock?

27.10.2026 21:09

Boeing shares plunge as 737 Max ramp-up delays overshadow top-line growth in 3Q

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026